Although clinically approved BTK inhibitors face limitations due to intolerance or resistance mutations (e.g., BTK-C481S), IKZF3 overexpression drives resistance in CLL (72). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.